CAM
ARTV

Cormorant Asset Management’s Artiva Biotherapeutics ARTV Stock Holding History

Cormorant Asset Management’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-103,633
Closed -$1.04M – 53
2024
Q4 		$1.04M Hold
103,633
– – 0.06% 47
2024
Q3 		$1.6M Buy
+103,633
New +$1.2M 0.08% 44

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Cormorant Asset Management's ARTV Position: Q1 2025 in Review

Cormorant Asset Management sold out of Artiva Biotherapeutics (ARTV) in Q1 2025, closing a stake of 103,633 shares — an estimated $1.04M sold.

Cormorant Asset Management first reported a position in ARTV in Q3 2024 and held it in 2 quarters. The position peaked at $1.6M in Q3 2024. 53 funds tracked by Wall St. Rank hold ARTV as of Q1 2025.

  • Cormorant Asset Management reported no remaining Artiva Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Cormorant Asset Management sold 103,633 Artiva Biotherapeutics shares in Q1 2025, an estimated $1.04M.
  • Cormorant Asset Management first reported a position in Artiva Biotherapeutics in Q3 2024 and held it in 2 quarters.
  • Cormorant Asset Management's Artiva Biotherapeutics position peaked at $1.6M in Q3 2024.
  • 53 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2025.

Based on Cormorant Asset Management's 13F filing for Q1 2025, filed 15 May 2025.